Search
Contact
21.09.2017 | KPMG Law Insights

Law of the health care industry – Hospitals in the area of conflict of different legal regulations

Hospitals in the area of conflict between different legal requirements

Hospitals are supposed to provide the best medical care for citizens, says social law. But without assuming a dominant position in the market, antitrust law demands. This leaves decision-makers on the hospital side sitting between two stools. And can do a lot wrong.

In early summer 2016, the German Federal Cartel Office contacted around 500 hospitals nationwide with an extensive questionnaire as part of a sector inquiry. The goal is to gain insight into the competitive framework. In addition to mergers, this specifically involves cooperations, the relevance of which under antitrust law has not yet been recognized by many players. The Federal Cartel Office intends to publish the results of the sector inquiry.

Social law ensures needs-based health care

In Germany, the provision of high-quality medical services (hospitals, contract physicians, providers of medical aids and remedies, etc.) to meet the needs of the population is governed by social legislation. Cooperation between hospitals is intended to benefit patients and is being promoted by politicians and authorities in many areas because it can improve the quality of medical care.

Antitrust law fights abuse of market power

What social law demands of hospital operators, antitrust law takes a critical view of, because a dominant market position is quickly achieved, especially in rural areas. The goal of antitrust law is to maintain functioning, unimpeded competition that is as diverse as possible. But it equally examines reciprocal specializations in service delivery or the development of new practices. Logistics, such as the purchase of goods and services, may also not be shared by two houses.

Sector inquiry assesses competitive framework

The competitive assessment also involves determining how hospitals seek to differentiate themselves from their competitors through their service offerings, quality management or specializations. The role of the various actors, such as medical staff, referring physicians, and emergency medical services, is also highlighted. Remuneration structures and the financial situation of hospitals are analyzed, as are the considerations that guide patients in their choice of hospital.

Conclusion

The Bundeskartellamt intends to use the sector inquiry to gain a better understanding of the hospital market and, if necessary, to adjust its decision-making practice in merger control proceedings and in the assessment of cooperations. The players concerned should therefore closely follow the announced report of the sector inquiry as well as the subsequent decision-making practice of the Federal Cartel Office.

However, even in the case of cooperation or merger projects, the antitrust component should be included in the considerations at an early stage in the run-up to the report. Those who do everything right according to the objectives of the social legislator can act unlawfully under antitrust law and risk fines and damage to their image. Legal advice is appropriate here.

Explore #more

09.01.2025 | In the media

KPMG Law strengthens Legal Transformation Managed Services and Legal Corporate Services with two new senior managers

On January 1, KPMG Law strengthened its Transformation Managed Services practice with Jana Sichelschmidt and its Corporate Services practice with Dr. Michaela Lenk. Both are…

06.01.2025 | Deal Notifications

KPMG Law advises on the sale of Käppler & Pausch GmbH

Gabriel Pausch, the co-founder and main shareholder of Käppler & Pausch GmbH, a system supplier for metal assemblies as well as metal and sheet metal…

03.01.2025 | In the media

Interview in Betrieb on the EU money laundering package and its impact

The EU anti-money laundering package harmonizes anti-money laundering and counter-terrorism rules in Europe and introduces new measures such as cash limits of €10,000, identification requirements…

02.01.2025 | In the media

KPMG Law Statement in eMagazin Immobilienanwälte: Creativity meets law in trademark protection

Four Frankfurt, Elbtower, Vonovia: real estate projects and companies are backed by constructs worth millions or even billions. In order to stand out from the…

20.12.2024 | KPMG Law Insights

The EU packaging regulation sets strict requirements for packaging

The EU has adopted the Packaging Regulation. After the European Parliament adopted the Commission’s draft on April 24, 2024, the EU member states also approved…

20.12.2024 | Deal Notifications

KPMG and KPMG Law supported the sale of circular Informationssysteme to the teccle group

Together with the corporate finance/M&A advisors of KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG), KPMG Law Rechtsanwaltsgesellschaft mbH (KPMG Law) advised the shareholders of circular Informationssysteme GmbH (circular)…

19.12.2024 | Press releases

KPMG Law defends Federal Motor Transport Authority against claim for damages in connection with the emissions scandal

The state is not liable to vehicle purchasers for damages. KPMG Law has defended the Federal Motor Transport Authority (KBA) against a civil plaintiff’s state…

18.12.2024 | KPMG Law Insights, KPMG Law Insights

MiCAR – What the new EU regulation means for crypto service providers and issuers

An EU regulation will soon come into force that will regulate crypto assets uniformly throughout Europe. It contains significant new obligations for issuers and crypto…

16.12.2024 | Deal Notifications

KPMG Law advises CERTANIA Holding GmbH on the acquisition of RASG Holdco Ltd.

KPMG Law Rechtsanwaltsgesellschaft mbH (KPMG Law) has provided legal advice to CERTANIA Holding GmbH, a platform of the Munich-based PE firm Greenpeak Partners, on the…

04.12.2024 | Deal Notifications

KPMG Law and KPMG advises Brain Biotech AG on license agreements and monetization of license rights

KPMG Law Rechtsanwaltsgesellschaft mbH and KPMG AG Wirtschaftsprüfungsgesellschaft (KPMG) advised Brain Biotech AG on the monetization of licensing rights with Royalty Pharma and the conclusion…

Contact

Dr. Gerrit Rixen

Partner
Head of Antitrust and Investment Control

Barbarossaplatz 1a
50674 Köln

Tel.: +49 221 2716891052
grixen@kpmg-law.com

© 2024 KPMG Law Rechtsanwaltsgesellschaft mbH, associated with KPMG AG Wirtschaftsprüfungsgesellschaft, a public limited company under German law and a member of the global KPMG organisation of independent member firms affiliated with KPMG International Limited, a Private English Company Limited by Guarantee. All rights reserved. For more details on the structure of KPMG’s global organisation, please visit https://home.kpmg/governance.

 KPMG International does not provide services to clients. No member firm is authorised to bind or contract KPMG International or any other member firm to any third party, just as KPMG International is not authorised to bind or contract any other member firm.

Scroll